TRANSITION THERAPEUTICS COMPLETES TARGET ENROLMENT FOR E1-I.N.T. TRIAL
Transition Therapeutics has completed target enrolment for an exploratory Phase IIa clinical trial of its regenerative therapy, E1-I.N.T. in Type I and Type II diabetes patients.
The trials are randomized, double-blind, controlled trials to evaluate the safety, tolerability and efficacy of daily E1-I.N.T. treatments for 28 days with a six-month follow-up.